SEC Filings
Filing | Description | Date Filed ![]() |
Size | View | ||||
---|---|---|---|---|---|---|---|---|
10-Q | quarterly report | Jul 28, 1998 | 75.7 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
S-8 | registration statement | Jun 16, 1998 | 40.0 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
10-Q | quarterly report | May 7, 1998 | 177.0 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
SC 13G | statement of beneficial ownership | Apr 6, 1998 | 45.1 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
10-K | annual report | Mar 31, 1998 | 303.8 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
DEF 14A | definitive proxy statement | Mar 30, 1998 | 126.0 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
8-K | current report | Mar 19, 1998 | 44.2 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
SC 13G/A | amended statement of beneficial ownership | Mar 10, 1998 | 34.2 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
SC 13D/A | amended general statement of beneficial ownership | Mar 2, 1998 | 50.8 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
SC 13G/A | amended statement of beneficial ownership | Feb 17, 1998 | 53.6 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
SC 13G/A | amended statement of beneficial ownership | Feb 13, 1998 | 31.3 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
SC 13G/A | amended statement of beneficial ownership | Feb 11, 1998 | 44.7 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
SC 13G | statement of beneficial ownership | Feb 11, 1998 | 33.5 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
10-Q | quarterly report | Nov 4, 1997 | 75.0 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
S-8 | registration statement | Sep 22, 1997 | 40.5 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
10-Q | quarterly report | Aug 11, 1997 | 75.9 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
10-Q | quarterly report | May 8, 1997 | 66.7 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
SC 13D | general statement of beneficial ownership | May 6, 1997 | 50.5 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
NTN 10K | notification of late filing | May 1, 1997 | 33.9 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
DEF 14A | definitive proxy statement | Apr 30, 1997 | 126.5 KB |
![]() ![]() ![]() ![]() |
![]() |
|||
|

Investors
© 2004-2018 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
About OncoGenex
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
For Patients
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
For Physicians
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
For Investors
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.